Barry Labinger has served as our President and Chief Executive Officer and as a member of our board of directors since December 2018. Before joining us, Mr. Labinger was President and Chief Executive Officer of Biothera Pharmaceuticals, Inc., a clinical stage cancer immunotherapy company focused on innate immune activation, from December 2015 through December 2018. Previously, Mr. Labinger was Executive Vice President and President, Bioscience Division at Emergent BioSolutions Inc., a specialty biopharmaceutical company developing cancer therapeutics, vaccines and antibody therapeutics for infectious diseases and other public health threats, from August 2013 through December 2015. Mr. Labinger holds a B.A. in economics from Northwestern University and an M.B.A. from Northwestern’s Kellogg Graduate School of Management, with concentrations in marketing, finance, and management policy. We believe Mr. Labinger is qualified to serve as a member of our board of directors due to his experience as an executive officer at other successful companies in the biopharmaceutical industry and his extensive experience in drug development in the area of immuno-oncology.
|
Jon Lieber has served as our interim Chief Financial Officer since July 1, 2019 by agreement with Danforth Advisors, LLC, or Danforth, a financial consultancy firm specializing working with life sciences companies. Since December 2018, Mr. Lieber has served as a Managing Director of Danforth. Prior to joining Danforth, Mr. Lieber was the Chief Financial Officer of Histogenics Corporation (now Ocugen, Inc.) from June 2015 through December 2018. From January 2014 through June 2015, Mr. Lieber was Senior Vice President and Chief Financial Officer of Metamark Genetics, Inc. He serves on the board of directors of Salarius Pharmaceuticals, Inc., a cancer-focused biotechnology company. Mr. Lieber is a seasoned executive with 25 years of experience in financial and executive management at emerging life science companies and in investment banking. Mr. Lieber holds a B.S. in business administration from Boston University and an M.B.A. in finance from New York University Stern School of Business.
|